Abuse-proofed dosage form
DCFirst Claim
Patent Images
1. A solid dosage form for oral administration with reduced potential for parenteral abuse, said dosage form comprising:
- (a) one or more active ingredients having potential for abuse selected from the group consisting of hydrocodone, morphine, oxycodone, tramadol, tapentadol, and pharmaceutically acceptable salts and solvates thereof; and
(b) one or more viscosity-increasing agents in a quantity such that an aqueous extract of a total content of the dosage form when comminuted and combined with 10 ml of water at 25°
C. forms a gel that can be drawn up into and injected back out of a hypodermic needle having a diameter of 0.9 mm, into a further quantity of water, wherein threads of the gel injected from said needle remain visible to the naked eye in said further quantity of water at 37°
C.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
-
Citations
20 Claims
-
1. A solid dosage form for oral administration with reduced potential for parenteral abuse, said dosage form comprising:
-
(a) one or more active ingredients having potential for abuse selected from the group consisting of hydrocodone, morphine, oxycodone, tramadol, tapentadol, and pharmaceutically acceptable salts and solvates thereof; and (b) one or more viscosity-increasing agents in a quantity such that an aqueous extract of a total content of the dosage form when comminuted and combined with 10 ml of water at 25°
C. forms a gel that can be drawn up into and injected back out of a hypodermic needle having a diameter of 0.9 mm, into a further quantity of water, wherein threads of the gel injected from said needle remain visible to the naked eye in said further quantity of water at 37°
C. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A solid dosage form for oral administration with reduced potential for parenteral abuse, said dosage form comprising:
-
(a) one or more active ingredients with potential for abuse selected from the group consisting of hydrocodone, morphine, oxycodone, tramadol, tapentadol, and pharmaceutically acceptable salts and/or solvates thereof; and (b) one or more viscosity-increasing agents in a quantity such that an aqueous extract of a total content of the dosage form when comminuted and combined with 10 ml of water at 25°
C. forms an injectable gel that can be drawn up into and injected back out of a syringe having a diameter of 0.9 mm, but wherein the injectable gel cannot be safely injected from said syringe into blood vessels of an abuser because the presence of the injectable gel in the abuser'"'"'s blood vessels would obstruct one or more of said abuser'"'"'s blood vessels. - View Dependent Claims (15, 16, 17, 18, 19, 20)
-
Specification